Cancer stem cells (CSC) are believed to be involved in tumor evasion of classical antitumor therapies and have thus become an attractive target for further improvement of anticancer strategies. However, the existence and identity of CSC are still a matter of controversy. In a systematic screen of 13 ovarian cancer cell lines we show that cells with stem cell properties are reliably detectable as a minor population, characterized by ABC transporter expression resulting in the side population (SP) phenotype. In different cell lines, either ABCG2 or ABCB1 was found to be responsible for this effect. Purified SP cells featured virtually all characteristics of bona fide CSC, including clonogenicity, asymmetric division and high tumorigenicity in vivo. Using in-depth phenotyping by multicolor flow cytometry, we found that among the investigated ovarian cancer cell lines the SP compartment exhibits tremendous heterogeneity and is composed of multiple phenotypically distinct subpopulations. Thus, our study confirms previous results showing that CSC are contained within the SP. However, the exact identity of the CSC is still disguised by the high complexity of the CSC-containing compartment. Further functional studies are needed to determine whether a single cellular subset can unambiguously be defined as CSC or whether multiple stem cell-like cells with different properties coexist. Moreover, the observed heterogeneity may reflect a high level of plasticity and likely influences tumor progression, escape from immune-surveillance and development of resistance to anticancer therapies and should therefore be considered in the development of new treatment strategies.

Department of Biology and Biomedical Centre Faculty of Medicine Pilsen Charles University Prague Pilsen Czech Republic

Department of Gynecology and Obstetrics Innsbruck Medical University Innsbruck Austria

Institute of Legal Medicine Innsbruck Medical University Innsbruck Austria

Internal Medicine 5 Innsbruck Medical University Innsbruck Austria

Internal Medicine 5 Innsbruck Medical University Innsbruck Austria Medical Clinic 3 Oncology Hematology and Rheumatology University Clinic Bonn Bonn Germany These authors contributed equally to this work

Internal Medicine 5 Innsbruck Medical University Innsbruck Austria Tyrolean Cancer Research Institute Innsbruck Austria

Internal Medicine 5 Innsbruck Medical University Innsbruck Austria Tyrolean Cancer Research Institute Innsbruck Austria These authors contributed equally to this work

Zobrazit více v PubMed

Clevers H. The cancer stem cell: premises, promises and challenges. Nature medicine. 2011;17(3):313–319. PubMed

Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nature reviews Cancer. 2008;8(10):755–768. PubMed

Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nature reviews Cancer. 2005;5(4):275–284. PubMed

Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, Bruns CJ, Heeschen C. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell stem cell. 2007;1(3):313–323. PubMed

Hamilton A, Helgason GV, Schemionek M, Zhang B, Myssina S, Allan EK, Nicolini FE, Muller-Tidow C, Bhatia R, Brunton VG, Koschmieder S, Holyoake TL. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood. 2012;119(6):1501–1510. PubMed PMC

Cannistra SA. Cancer of the ovary. The New England journal of medicine. 2004;351(24):2519–2529. PubMed

Cooke SL, Brenton JD. Evolution of platinum resistance in high-grade serous ovarian cancer. The lancet oncology. 2011;12(12):1169–1174. PubMed

Zeimet AG, Reimer D, Sopper S, Boesch M, Martowicz A, Roessler J, Wiedemair AM, Rumpold H, Untergasser G, Concin N, Hofstetter G, Muller-Holzner E, Fiegl H, Marth C, Wolf D, Pesta M, et al. Ovarian cancer stem cells. Neoplasma. 2012;59(6):747–755. PubMed

Steffensen KD, Alvero AB, Yang Y, Waldstrom M, Hui P, Holmberg JC, Silasi DA, Jakobsen A, Rutherford T, Mor G. Prevalence of epithelial ovarian cancer stem cells correlates with recurrence in early-stage ovarian cancer. Journal of oncology. 2011;2011:620523. PubMed PMC

Meng E, Long B, Sullivan P, McClellan S, Finan MA, Reed E, Shevde L, Rocconi RP. CD44+/CD24- ovarian cancer cells demonstrate cancer stem cell properties and correlate to survival. Clinical & experimental metastasis. 2012;29(8):939–948. PubMed

Kryczek I, Liu S, Roh M, Vatan L, Szeliga W, Wei S, Banerjee M, Mao Y, Kotarski J, Wicha MS, Liu R, Zou W. Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells. International journal of cancer Journal international du cancer. 2012;130(1):29–39. PubMed PMC

Szotek PP, Pieretti-Vanmarcke R, Masiakos PT, Dinulescu DM, Connolly D, Foster R, Dombkowski D, Preffer F, Maclaughlin DT, Donahoe PK. Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. Proc Natl Acad Sci U S A. 2006;103(30):11154–11159. PubMed PMC

Hu L, McArthur C, Jaffe RB. Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant. Br J Cancer. 2010;102(8):1276–1283. PubMed PMC

Rizzo S, Hersey JM, Mellor P, Dai W, Santos-Silva A, Liber D, Luk L, Titley I, Carden CP, Box G, Hudson DL, Kaye SB, Brown R. Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2. Molecular cancer therapeutics. 2011;10(2):325–335. PubMed PMC

Gao MQ, Choi YP, Kang S, Youn JH, Cho NH. CD24+ cells from hierarchically organized ovarian cancer are enriched in cancer stem cells. Oncogene. 2010;29(18):2672–2680. PubMed

Rabindran SK, Ross DD, Doyle LA, Yang W, Greenberger LM. Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. Cancer Res. 2000;60(1):47–50. PubMed

Golebiewska A, Brons NH, Bjerkvig R, Niclou SP. Critical appraisal of the side population assay in stem cell and cancer stem cell research. Cell stem cell. 2011;8(2):136–147. PubMed

Greve B, Kelsch R, Spaniol K, Eich HT, Gotte M. Flow cytometry in cancer stem cell analysis and separation. Cytometry Part A : the journal of the International Society for Analytical Cytology. 2012;81(4):284–293. PubMed

Jaiswal KR, Xin HW, Anderson A, Wiegand G, Kim B, Miller T, Hari D, Ray S, Koizumi T, Rudloff U, Thorgeirsson SS, Avital I. Comparative testing of various pancreatic cancer stem cells results in a novel class of pancreatic-cancer-initiating cells. Stem cell research. 2012;9(3):249–260. PubMed PMC

Fogel M, Gutwein P, Mechtersheimer S, Riedle S, Stoeck A, Smirnov A, Edler L, Ben-Arie A, Huszar M, Altevogt P. L1 expression as a predictor of progression and survival in patients with uterine and ovarian carcinomas. Lancet. 2003;362(9387):869–875. PubMed

Matei D, Emerson RE, Lai YC, Baldridge LA, Rao J, Yiannoutsos C, Donner DD. Autocrine activation of PDGFRalpha promotes the progression of ovarian cancer. Oncogene. 2006;25(14):2060–2069. PubMed

Zeisberg M, Neilson EG. Biomarkers for epithelial-mesenchymal transitions. J Clin Invest. 2009;119(6):1429–1437. PubMed PMC

Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verastegui E, Zlotnik A. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001;410(6824):50–56. PubMed

Pamer E, Cresswell P. Mechanisms of MHC class I--restricted antigen processing. Annual review of immunology. 1998;16:323–358. PubMed

Strasser A, Jost PJ, Nagata S. The many roles of FAS receptor signaling in the immune system. Immunity. 2009;30(2):180–192. PubMed PMC

Domcke S, Sinha R, Levine DA, Sander C, Schultz N. Evaluating cell lines as tumour models by comparison of genomic profiles. Nature communications. 2013;4:2126. PubMed PMC

Anglesio MS, Wiegand KC, Melnyk N, Chow C, Salamanca C, Prentice LM, Senz J, Yang W, Spillman MA, Cochrane DR, Shumansky K, Shah SP, Kalloger SE, Huntsman DG. Type-specific cell line models for type-specific ovarian cancer research. PloS one. 2013;8(9):e72162. PubMed PMC

Fukunaga-Kalabis M, Martinez G, Nguyen TK, Kim D, Santiago-Walker A, Roesch A, Herlyn M. Tenascin-C promotes melanoma progression by maintaining the ABCB5-positive side population. Oncogene. 2010;29(46):6115–6124. PubMed PMC

Masters JR. Human cancer cell lines: fact and fantasy. Nature reviews Molecular cell biology. 2000;1(3):233–236. PubMed

Moserle L, Indraccolo S, Ghisi M, Frasson C, Fortunato E, Canevari S, Miotti S, Tosello V, Zamarchi R, Corradin A, Minuzzo S, Rossi E, Basso G, Amadori A. The side population of ovarian cancer cells is a primary target of IFN-alpha antitumor effects. Cancer Res. 2008;68(14):5658–5668. PubMed

Schatton T, Murphy GF, Frank NY, Yamaura K, Waaga-Gasser AM, Gasser M, Zhan Q, Jordan S, Duncan LM, Weishaupt C, Fuhlbrigge RC, Kupper TS, Sayegh MH, Frank MH. Identification of cells initiating human melanomas. Nature. 2008;451(7176):345–349. PubMed PMC

Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF, Simeone DM. Identification of pancreatic cancer stem cells. Cancer Res. 2007;67(3):1030–1037. PubMed

Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ. Efficient tumour formation by single human melanoma cells. Nature. 2008;456(7222):593–598. PubMed PMC

Stewart JM, Shaw PA, Gedye C, Bernardini MQ, Neel BG, Ailles LE. Phenotypic heterogeneity and instability of human ovarian tumor-initiating cells. Proc Natl Acad Sci U S A. 2011;108(16):6468–6473. PubMed PMC

Stadlmann S, Feichtinger H, Mikuz G, Marth C, Zeimet AG, Herold M, Knabbe C, Offner FA. Interactions of human peritoneal mesothelial cells with serous ovarian cancer cell spheroids-evidence for a mechanical and paracrine barrier function of the peritoneal mesothelium. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2014;24(2):192–200. PubMed

Huntly BJ, Gilliland DG. Leukaemia stem cells and the evolution of cancer-stem-cell research. Nature reviews Cancer. 2005;5(4):311–321. PubMed

Yegnasubramanian S, Haffner MC, Zhang Y, Gurel B, Cornish TC, Wu Z, Irizarry RA, Morgan J, Hicks J, DeWeese TL, Isaacs WB, Bova GS, De Marzo AM, Nelson WG. DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity. Cancer Res. 2008;68(21):8954–8967. PubMed PMC

Campbell PJ, Yachida S, Mudie LJ, Stephens PJ, Pleasance ED, Stebbings LA, Morsberger LA, Latimer C, McLaren S, Lin ML, McBride DJ, Varela I, Nik-Zainal SA, Leroy C, Jia M, Menzies A, et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature. 2010;467(7319):1109–1113. PubMed PMC

Gupta PB, Fillmore CM, Jiang G, Shapira SD, Tao K, Kuperwasser C, Lander ES. Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell. 2011;146(4):633–644. PubMed

Dexter DL, Leith JT. Tumor heterogeneity and drug resistance. J Clin Oncol. 1986;4(2):244–257. PubMed

Turner NC, Reis-Filho JS. Genetic heterogeneity and cancer drug resistance. The lancet oncology. 2012;13(4):e178–185. PubMed

Marchitti SA, Brocker C, Stagos D, Vasiliou V. Non-P450 aldehyde oxidizing enzymes: the aldehyde dehydrogenase superfamily. Expert opinion on drug metabolism & toxicology. 2008;4(6):697–720. PubMed PMC

So T, Takenoyama M, Mizukami M, Ichiki Y, Sugaya M, Hanagiri T, Sugio K, Yasumoto K. Haplotype loss of HLA class I antigen as an escape mechanism from immune attack in lung cancer. Cancer Res. 2005;65(13):5945–5952. PubMed

Owen-Schaub LB. Fas function and tumor progression: use it and lose it. Cancer Cell. 2002;2(2):95–96. PubMed

Chen L, Park SM, Tumanov AV, Hau A, Sawada K, Feig C, Turner JR, Fu YX, Romero IL, Lengyel E, Peter ME. CD95 promotes tumour growth. Nature. 2010;465(7297):492–496. PubMed PMC

Bendall SC, Nolan GP. From single cells to deep phenotypes in cancer. Nature biotechnology. 2012;30(7):639–647. PubMed

Marth C, Zeimet AG, Herold M, Brumm C, Windbichler G, Muller-Holzner E, Offner F, Feichtinger H, Zwierzina H, Daxenbichler G. Different effects of interferons, interleukin-1beta and tumor necrosis factor-alpha in normal (OSE) and malignant human ovarian epithelial cells. International journal of cancer Journal international du cancer. 1996;67(6):826–830. PubMed

Buick RN, Pullano R, Trent JM. Comparative properties of five human ovarian adenocarcinoma cell lines. Cancer Res. 1985;45(8):3668–3676. PubMed

Benard J, Da Silva J, De Blois MC, Boyer P, Duvillard P, Chiric E, Riou G. Characterization of a human ovarian adenocarcinoma line, IGROV1, in tissue culture and in nude mice. Cancer Res. 1985;45(10):4970–4979. PubMed

Wallen JW, Cate RL, Kiefer DM, Riemen MW, Martinez D, Hoffman RM, Donahoe PK, Von Hoff DD, Pepinsky B, Oliff A. Minimal antiproliferative effect of recombinant mullerian inhibiting substance on gynecological tumor cell lines and tumor explants. Cancer Res. 1989;49(8):2005–2011. PubMed

Boesch M, Reimer D, Rumpold H, Zeimet AG, Sopper S, Wolf D. DyeCycle Violet used for side population detection is a substrate of P-glycoprotein. Cytometry Part A : the journal of the International Society for Analytical Cytology. 2012;81(6):517–522. PubMed

Roederer M, Nozzi JL, Nason MC. SPICE: exploration and analysis of post-cytometric complex multivariate datasets. Cytometry Part A : the journal of the International Society for Analytical Cytology. 2011;79(2):167–174. PubMed PMC

Evaluation of Vav3.1 as prognostic marker in endometrial cancer